Digital

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
AIAI Proteins

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Astellas Pharma Inc. (TYO: 4503) announced a collaboration with AI Proteins, a Boston‑based computational drug discovery company, in a deal with a total potential value exceeding USD 400 million. Under…

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
AIAstraZeneca

HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials
CancerCAR-T

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug
HKG: 9995Ophthalmology

RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug

China's WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services
AIIPO

China’s WeiMai Plans Hong Kong IPO to Expand AI-Powered Healthcare Services

Show More